Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib with Letrozole and Palbociclib in Breast Cancer
NCT03128619Phase 1Terminated
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Aug 2017
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of copanlisib in breast cancer (4 arms), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Change in Ki-67 expression at 2 weeks and Incidence of dose-limiting toxicities up to 112 days. Started Aug 2017; status: terminated.
02
Drugs
copanlisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03128619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03128619.